<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - LEVONORGESTREL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>LEVONORGESTREL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Emergency contraception</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1.5 mg for 1 dose, taken as soon as possible after coitus, preferably within 12 hours but no later than after 72 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Contraception</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1 tablet daily starting on day 1 of the cycle then continuously, dose is to be taken at the same time each day, if administration delayed for 3 hours or more it should be regarded as a "missed pill".</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Not known to be harmful.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">vaginal</ph> use</h3>
              <p>If an intra-uterine device fails and the woman wishes to continue to full-term the device should be removed in the first trimester if possible.</p><p>Avoid; if pregnancy occurs remove intra-uterine system.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Caution in severe liver disease and recurrent cholestatic jaundice.</p><p>Avoid in liver tumour.</p>
            </section>
      </section>


      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Depression (sometimes severe), headache, nausea,
              </p>
              <p>
                <strong>notKnown:</strong> Vomiting,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> abdominal pain, acne, alopecia, back pain, breast pain, changes in the pattern and duration of menstrual bleeding (spotting or prolonged bleeding), expulsion, hirsutism, migraine, nervousness, pelvic pain, peripheral oedema, salpingitis,
              </p>
              <p>
                <strong>uncommon:</strong> abdominal distension, cervicitis, eczema, pelvic inflammatory disease, pruritus, skin hyperpigmentation,
              </p>
              <p>
                <strong>rare:</strong> rash, uterine perforation,
              </p>
              <p>
                <strong>notKnown:</strong> allergy, bleeding (on insertion), cervical perforation, displacement, dysmenorrhoea, epileptic seizures (on insertion), functional ovarian cysts (usually asymptomatic and usually resolve spontaneously&#8212;ultrasound monitoring recommended), menorrhagia, pain (on insertion, alleviated by NSAID such as ibuprofen 30 minutes before insertion), pelvic infection may be exacerbated, vasovagal attack (on insertion), breast discomfort, breast tenderness, changes in libido, disturbances of appetite, dizziness, fatigue, menstrual irregularities, skin disorders,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intra-uterine</ph> use</h3>
              <p>Endometrial disorders should be ruled out before insertion and the patient should be fully counselled (and provided with a patient information leaflet). Improvement in progestogenic side-effects, such as mastalgia and in the bleeding pattern may often become very light or absent.</p>
            </section>
            <section class="advice">
                <h3>Breast cancer</h3>
              <p>There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.</p><p>Although the progestogen-only intra-uterine system produces little systemic progestogenic activity, it is usually avoided for 5 years after any evidence of breast cancer. However, the system can be considered for a woman in long-term remission from breast cancer who has menorrhagia and requires effective contraception.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intra-uterine</ph> use</h3>
              <p>Removal of the intra-uterine system should be considered if the patient experiences migraine or severe headache, jaundice, marked increase of blood pressure, or severe arterial disease.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intra-uterine</ph> use</h3>
              <p>
            <i>The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.</i>
            </p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
              <p>When used as an oral contraceptive, the following advice is recommended &#8216;If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days&#8217;.</p><p>The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Diarrhoea and vomiting with use as an oral contraceptive</h3>
              <p>Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Contraception</ph></h3>
                <p class="title">Starting routine</p>
              <p>One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not necessary when initiating treatment.</p><p outputclass="title">Changing from a combined oral contraceptive</p> <p>Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).</p><p outputclass="title">After childbirth</p> <p>Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">intra-uterine</ph> use</h3>
              <p>Counsel women to seek medical attention promptly in case of significant symptoms, especially pain.</p><p>Patient counselling advised.</p><p>Patient information leaflet to be provided.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Emergency contraception</ph></h3>
              <p>If vomiting occurs within 2 hours of taking levonorgestrel, a replacement dose should be given.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Emergency contraception</ph></h3>
              <ul>
            <li>When prescribing or supplying hormonal emergency contraception, women should be advised:</li>
            <li>that their next period may be early or late;</li>
            <li>that a barrier method of contraception needs to be used until the next period;</li>
            <li>to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;</li>
            <li>to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).</li>
            </ul>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <h3 class="specificity">With <ph outputclass="route">intra-uterine</ph> use</h3>
                <p class="title">MHRA/CHM advice (June 2015) Intra-uterine contraception: uterine perforation&amp;#8212;updated information on risk factors</p>
              <p>Uterine perforation most often occurs during insertion, but might not be detected until sometime later. The risk of uterine perforation is increased when the device is inserted up to 36 weeks postpartum or in patients who are breastfeeding. Before inserting an intra-uterine contraceptive device, inform patients that perforation occurs in approximately 1 in every 1000 insertions and signs and symptoms include:</p><ul>
            <li>severe pelvic pain after insertion (worse than period cramps);</li>
            <li>pain or increased bleeding after insertion which continues for more than a few weeks;</li>
            <li>sudden changes in periods;</li>
            <li>pain during intercourse;</li>
            <li>unable to feel the threads.</li>
            </ul><p>Patients should be informed on how to check their threads and to arrange a check-up if threads cannot be felt, especially if they also have significant pain. Partial perforation may occur even if the threads can be seen; consider this if there is severe pain following insertion and perform an ultrasound.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intra-uterine use:</strong>
            anaemia
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            anticoagulant therapy (avoid if possible)
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            diabetes
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            disease-induced immunosuppression (risk of infection&#8212;avoid if marked immunosuppression)
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            drug-induced immunosuppression (risk of infection&#8212;avoid if marked immunosuppression)
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            endometriosis
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            epilepsy (risk of seizure at time of insertion)
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            fertility problems
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            history of pelvic inflammatory disease
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            increased risk of expulsion if inserted before uterine involution
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            menorrhagia (progestogen intra-uterine system might be preferable)
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            nulliparity
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            severe cervical stenosis
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            severe primary dysmenorrhoea
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            severely scarred uterus (including after endometrial resection)
          </li>
          <li>
              <strong>With intra-uterine use:</strong>
            young age
          </li>
        </ul>
        <ul>
          <li>
              <strong>When used for contraception:</strong>
            active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice
          </li>
          <li>
              <strong>When used for contraception:</strong>
            arterial disease
          </li>
          <li>
              <strong>When used for contraception:</strong>
            functional ovarian cysts
          </li>
          <li>
              <strong>When used for contraception:</strong>
            history of jaundice in pregnancy
          </li>
          <li>
              <strong>When used for contraception:</strong>
            malabsorption syndromes
          </li>
          <li>
              <strong>When used for contraception:</strong>
            past ectopic pregnancy
          </li>
          <li>
              <strong>When used for contraception:</strong>
            sex-steroid dependent cancer
          </li>
          <li>
              <strong>When used for contraception:</strong>
            systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies
          </li>
          <li>
              <strong>When used for emergency contraception:</strong>
            active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice
          </li>
          <li>
              <strong>When used for emergency contraception:</strong>
            past ectopic pregnancy
          </li>
          <li>
              <strong>When used for emergency contraception:</strong>
            severe malabsorption syndromes
          </li>
        </ul>
        <ul>
          <li>
              <strong>With <ph outputclass="route">oral</ph> use:</strong>
            <p>The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes meillitus and migraine; evidence for caution in these conditions is unsatisfactory.</p>
          </li>
          <li>
            <p>The main excess risk of infection occurs in the first 20 days after insertion and is believed to be related to existing carriage of a sexually transmitted infection. Women are considered to be at a higher risk of sexually transmitted infections if:</p><ul>
        <li> they are under 25 years old <i>or</i>
        </li>
        <li>they are over 25 years old <i>and</i>
        <ul>
        <li>have a new partner <i>or</i>
        </li>
        <li>have had more than one partner in the past year <i>or</i>
        </li>
        <li>their regular partner has other partners.</li>
        </ul>
        </li>
        </ul><p>In these women, pre-insertion screening (for chlamydia and, depending on sexual history and local prevalence of disease, <ph outputclass="organism">
        <i>Neisseria gonorrhoeae</i>
        </ph>) should be performed. If results are unavailable at the time of fitting an intrauterine device for emergency contraception, appropriate prophylactic antibacterial cover should be given. The woman should be advised to attend <i>as an emergency</i> if she experiences sustained pain during the next 20 days.</p><p>An intra-uterine device should not be removed in mid-cycle unless an additional contraceptive was used for the previous 7 days. If removal is essential post-coital contraception should be considered.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
      </section>









      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <p>
            <i>Levonelle</i>
            <tm tmtype="reg"/>
            <i>One Step</i> can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of LEVONORGESTREL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77217"><a href="../medicinalForm/PHP77217.html" data-target="#PHP77217" data-action="load">Tablet</a></div>
            <div id="PHP77225"><a href="../medicinalForm/PHP77225.html" data-target="#PHP77225" data-action="load">Intrauterine device</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
